Preclinical Evaluation of MicroRNA-34b/c Delivery for Malignant Pleural Mesothelioma
この論文をさがす
抄録
The microRNA-34s (miR-34s) have p53 response elements in their 5ʼ-flanking regions and demonstrate tumor-suppressive functions. In malignant pleural mesothelioma (MPM), we previously reported that expression of miR-34b and miR-34c (miR-34b/c) was frequently downregulated by methylation in MPM cell lines and primary tumors. The forced overexpression of miR-34b/c showed significant antitumor effects with the induction of apoptosis in MPM cells. In this study, we examined the in vivo antitumor effects of miR-34b/c using adenovirus vector on MPM. We subcutaneously transplanted NCI-H290, a human MPM cell line, into BALB/C mice and injected adenovirus vector expressing miR-34b/c, luciferase driven by the cytomegalovirus promoter (Ad-miR-34b/c or Ad-Luc), or PBS control into tumors over 5mm in diameter. A statistically significant growth inhibition of the tumor volume was observed in the Ad-miR-34b/c group from day 6 onward compared to the Ad-Luc group. The inhibition rate of Ad-miR-34b/c, compared to the tumor volume treated with Ad-Luc, was 58.6% on day 10 and 54.7% on day13. Our results indicate that adenovirus-mediated miR-34b/c gene therapy could be useful for the clinical treatment of MPM.
収録刊行物
-
- Acta Medica Okayama
-
Acta Medica Okayama 68 (1), 23-26, 2014-02
Okayama University Medical School
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390290699796060160
-
- NII論文ID
- 120005372648
-
- NII書誌ID
- AA00508441
-
- ISSN
- 0386300X
-
- PubMed
- 24553485
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- IRDB
- PubMed
- CiNii Articles